nodes	percent_of_prediction	percent_of_DWPC	metapath
Trisalicylate-choline—PTGS2—thyroid cancer	0.869	1	CbGaD
Trisalicylate-choline—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.008	0.155	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00635	0.123	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00601	0.116	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00477	0.0923	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00327	0.0632	CbGpPWpGaD
Trisalicylate-choline—Hypocalcaemia—Vandetanib—thyroid cancer	0.00304	0.0405	CcSEcCtD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00284	0.055	CbGpPWpGaD
Trisalicylate-choline—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00269	0.0358	CcSEcCtD
Trisalicylate-choline—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00259	0.0501	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00217	0.042	CbGpPWpGaD
Trisalicylate-choline—Magnesium salicylate—PTGS2—thyroid cancer	0.0021	0.54	CrCbGaD
Trisalicylate-choline—Lethargy—Vandetanib—thyroid cancer	0.00206	0.0275	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Sorafenib—thyroid cancer	0.00205	0.0273	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Sorafenib—thyroid cancer	0.00179	0.0239	CcSEcCtD
Trisalicylate-choline—Salsalate—PTGS2—thyroid cancer	0.00179	0.46	CrCbGaD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00172	0.0333	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00168	0.0326	CbGpPWpGaD
Trisalicylate-choline—Epistaxis—Vandetanib—thyroid cancer	0.00147	0.0196	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Vandetanib—thyroid cancer	0.00132	0.0176	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Sorafenib—thyroid cancer	0.00125	0.0166	CcSEcCtD
Trisalicylate-choline—Hypothermia—Epirubicin—thyroid cancer	0.00124	0.0165	CcSEcCtD
Trisalicylate-choline—Body temperature decreased—Epirubicin—thyroid cancer	0.00124	0.0165	CcSEcCtD
Trisalicylate-choline—Gastric ulcer—Epirubicin—thyroid cancer	0.00119	0.0159	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Vandetanib—thyroid cancer	0.00119	0.0159	CcSEcCtD
Trisalicylate-choline—Body temperature decreased—Doxorubicin—thyroid cancer	0.00115	0.0153	CcSEcCtD
Trisalicylate-choline—Hypothermia—Doxorubicin—thyroid cancer	0.00115	0.0153	CcSEcCtD
Trisalicylate-choline—Abdominal discomfort—Sorafenib—thyroid cancer	0.00113	0.0151	CcSEcCtD
Trisalicylate-choline—Gastric ulcer—Doxorubicin—thyroid cancer	0.00111	0.0147	CcSEcCtD
Trisalicylate-choline—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.00108	0.0209	CbGpPWpGaD
Trisalicylate-choline—Burning sensation—Epirubicin—thyroid cancer	0.000999	0.0133	CcSEcCtD
Trisalicylate-choline—Oedema—Vandetanib—thyroid cancer	0.000993	0.0132	CcSEcCtD
Trisalicylate-choline—Epistaxis—Sorafenib—thyroid cancer	0.000991	0.0132	CcSEcCtD
Trisalicylate-choline—Burning sensation—Doxorubicin—thyroid cancer	0.000925	0.0123	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Sorafenib—thyroid cancer	0.000892	0.0119	CcSEcCtD
Trisalicylate-choline—Tinnitus—Sorafenib—thyroid cancer	0.00088	0.0117	CcSEcCtD
Trisalicylate-choline—Flushing—Sorafenib—thyroid cancer	0.000875	0.0117	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Vandetanib—thyroid cancer	0.000875	0.0117	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Vandetanib—thyroid cancer	0.000864	0.0115	CcSEcCtD
Trisalicylate-choline—Stinging—Epirubicin—thyroid cancer	0.000857	0.0114	CcSEcCtD
Trisalicylate-choline—Pain—Vandetanib—thyroid cancer	0.00085	0.0113	CcSEcCtD
Trisalicylate-choline—Constipation—Vandetanib—thyroid cancer	0.00085	0.0113	CcSEcCtD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000845	0.0163	CbGpPWpGaD
Trisalicylate-choline—Erythema—Sorafenib—thyroid cancer	0.000821	0.0109	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Sorafenib—thyroid cancer	0.000804	0.0107	CcSEcCtD
Trisalicylate-choline—Stinging—Doxorubicin—thyroid cancer	0.000793	0.0106	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Epirubicin—thyroid cancer	0.000758	0.0101	CcSEcCtD
Trisalicylate-choline—Pruritus—Vandetanib—thyroid cancer	0.000703	0.00937	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000702	0.00935	CcSEcCtD
Trisalicylate-choline—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000701	0.0135	CbGpPWpGaD
Trisalicylate-choline—Injection site reaction—Epirubicin—thyroid cancer	0.00069	0.0092	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Vandetanib—thyroid cancer	0.00068	0.00906	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Epirubicin—thyroid cancer	0.000663	0.00883	CcSEcCtD
Trisalicylate-choline—Shock—Sorafenib—thyroid cancer	0.000659	0.00879	CcSEcCtD
Trisalicylate-choline—Dizziness—Vandetanib—thyroid cancer	0.000657	0.00876	CcSEcCtD
Trisalicylate-choline—Anorexia—Sorafenib—thyroid cancer	0.000639	0.00851	CcSEcCtD
Trisalicylate-choline—Injection site reaction—Doxorubicin—thyroid cancer	0.000639	0.00851	CcSEcCtD
Trisalicylate-choline—Oesophagitis—Epirubicin—thyroid cancer	0.000634	0.00845	CcSEcCtD
Trisalicylate-choline—Vomiting—Vandetanib—thyroid cancer	0.000632	0.00842	CcSEcCtD
Trisalicylate-choline—Ecchymosis—Epirubicin—thyroid cancer	0.000628	0.00836	CcSEcCtD
Trisalicylate-choline—Rash—Vandetanib—thyroid cancer	0.000626	0.00835	CcSEcCtD
Trisalicylate-choline—Dermatitis—Vandetanib—thyroid cancer	0.000626	0.00834	CcSEcCtD
Trisalicylate-choline—Headache—Vandetanib—thyroid cancer	0.000622	0.00829	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Doxorubicin—thyroid cancer	0.000613	0.00817	CcSEcCtD
Trisalicylate-choline—Nausea—Vandetanib—thyroid cancer	0.00059	0.00786	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Sorafenib—thyroid cancer	0.00059	0.00786	CcSEcCtD
Trisalicylate-choline—Oesophagitis—Doxorubicin—thyroid cancer	0.000587	0.00782	CcSEcCtD
Trisalicylate-choline—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000586	0.0113	CbGpPWpGaD
Trisalicylate-choline—Decreased appetite—Sorafenib—thyroid cancer	0.000583	0.00776	CcSEcCtD
Trisalicylate-choline—Ecchymosis—Doxorubicin—thyroid cancer	0.000581	0.00774	CcSEcCtD
Trisalicylate-choline—Constipation—Sorafenib—thyroid cancer	0.000573	0.00764	CcSEcCtD
Trisalicylate-choline—Pain—Sorafenib—thyroid cancer	0.000573	0.00764	CcSEcCtD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000549	0.0106	CbGpPWpGaD
Trisalicylate-choline—Urticaria—Sorafenib—thyroid cancer	0.000532	0.0071	CcSEcCtD
Trisalicylate-choline—Lethargy—Epirubicin—thyroid cancer	0.000514	0.00685	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000494	0.00955	CbGpPWpGaD
Trisalicylate-choline—Lethargy—Doxorubicin—thyroid cancer	0.000476	0.00634	CcSEcCtD
Trisalicylate-choline—Pruritus—Sorafenib—thyroid cancer	0.000474	0.00632	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Epirubicin—thyroid cancer	0.00046	0.00613	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Sorafenib—thyroid cancer	0.000459	0.00611	CcSEcCtD
Trisalicylate-choline—Dizziness—Sorafenib—thyroid cancer	0.000443	0.00591	CcSEcCtD
Trisalicylate-choline—Asthma—Epirubicin—thyroid cancer	0.000436	0.0058	CcSEcCtD
Trisalicylate-choline—Vomiting—Sorafenib—thyroid cancer	0.000426	0.00568	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000426	0.00568	CcSEcCtD
Trisalicylate-choline—Rash—Sorafenib—thyroid cancer	0.000423	0.00563	CcSEcCtD
Trisalicylate-choline—Dermatitis—Sorafenib—thyroid cancer	0.000422	0.00563	CcSEcCtD
Trisalicylate-choline—Headache—Sorafenib—thyroid cancer	0.00042	0.0056	CcSEcCtD
Trisalicylate-choline—Asthma—Doxorubicin—thyroid cancer	0.000403	0.00537	CcSEcCtD
Trisalicylate-choline—Nausea—Sorafenib—thyroid cancer	0.000398	0.0053	CcSEcCtD
Trisalicylate-choline—Weight increased—Epirubicin—thyroid cancer	0.000396	0.00528	CcSEcCtD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000393	0.0076	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000389	0.00753	CbGpPWpGaD
Trisalicylate-choline—Drowsiness—Epirubicin—thyroid cancer	0.000388	0.00518	CcSEcCtD
Trisalicylate-choline—Sweating—Epirubicin—thyroid cancer	0.000372	0.00496	CcSEcCtD
Trisalicylate-choline—Weight increased—Doxorubicin—thyroid cancer	0.000367	0.00489	CcSEcCtD
Trisalicylate-choline—Epistaxis—Epirubicin—thyroid cancer	0.000366	0.00488	CcSEcCtD
Trisalicylate-choline—Drowsiness—Doxorubicin—thyroid cancer	0.000359	0.00479	CcSEcCtD
Trisalicylate-choline—Hepatitis—Epirubicin—thyroid cancer	0.000349	0.00465	CcSEcCtD
Trisalicylate-choline—Sweating—Doxorubicin—thyroid cancer	0.000344	0.00459	CcSEcCtD
Trisalicylate-choline—Epistaxis—Doxorubicin—thyroid cancer	0.000339	0.00452	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000337	0.00653	CbGpPWpGaD
Trisalicylate-choline—Erythema multiforme—Epirubicin—thyroid cancer	0.00033	0.00439	CcSEcCtD
Trisalicylate-choline—Tinnitus—Epirubicin—thyroid cancer	0.000325	0.00433	CcSEcCtD
Trisalicylate-choline—Flushing—Epirubicin—thyroid cancer	0.000324	0.00431	CcSEcCtD
Trisalicylate-choline—Hepatitis—Doxorubicin—thyroid cancer	0.000323	0.0043	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00031	0.006	CbGpPWpGaD
Trisalicylate-choline—Erythema multiforme—Doxorubicin—thyroid cancer	0.000305	0.00406	CcSEcCtD
Trisalicylate-choline—Erythema—Epirubicin—thyroid cancer	0.000303	0.00404	CcSEcCtD
Trisalicylate-choline—Tinnitus—Doxorubicin—thyroid cancer	0.000301	0.00401	CcSEcCtD
Trisalicylate-choline—Flushing—Doxorubicin—thyroid cancer	0.000299	0.00399	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Epirubicin—thyroid cancer	0.000297	0.00396	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000292	0.00564	CbGpPWpGaD
Trisalicylate-choline—Erythema—Doxorubicin—thyroid cancer	0.000281	0.00374	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Doxorubicin—thyroid cancer	0.000275	0.00366	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000257	0.00497	CbGpPWpGaD
Trisalicylate-choline—Confusional state—Epirubicin—thyroid cancer	0.00025	0.00333	CcSEcCtD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000248	0.00479	CbGpPWpGaD
Trisalicylate-choline—Oedema—Epirubicin—thyroid cancer	0.000248	0.0033	CcSEcCtD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000246	0.00476	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000245	0.00473	CbGpPWpGaD
Trisalicylate-choline—Shock—Epirubicin—thyroid cancer	0.000244	0.00325	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Epirubicin—thyroid cancer	0.000239	0.00319	CcSEcCtD
Trisalicylate-choline—Anorexia—Epirubicin—thyroid cancer	0.000236	0.00315	CcSEcCtD
Trisalicylate-choline—Hypotension—Epirubicin—thyroid cancer	0.000231	0.00308	CcSEcCtD
Trisalicylate-choline—Confusional state—Doxorubicin—thyroid cancer	0.000231	0.00308	CcSEcCtD
Trisalicylate-choline—Oedema—Doxorubicin—thyroid cancer	0.000229	0.00305	CcSEcCtD
Trisalicylate-choline—Shock—Doxorubicin—thyroid cancer	0.000225	0.003	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000222	0.00295	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000221	0.00428	CbGpPWpGaD
Trisalicylate-choline—Somnolence—Epirubicin—thyroid cancer	0.00022	0.00293	CcSEcCtD
Trisalicylate-choline—Anorexia—Doxorubicin—thyroid cancer	0.000218	0.00291	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Epirubicin—thyroid cancer	0.000218	0.00291	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Epirubicin—thyroid cancer	0.000215	0.00287	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000214	0.00415	CbGpPWpGaD
Trisalicylate-choline—Hypotension—Doxorubicin—thyroid cancer	0.000214	0.00285	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000213	0.00412	CbGpPWpGaD
Trisalicylate-choline—Pain—Epirubicin—thyroid cancer	0.000212	0.00282	CcSEcCtD
Trisalicylate-choline—Constipation—Epirubicin—thyroid cancer	0.000212	0.00282	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Epirubicin—thyroid cancer	0.000204	0.00272	CcSEcCtD
Trisalicylate-choline—Somnolence—Doxorubicin—thyroid cancer	0.000204	0.00272	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Doxorubicin—thyroid cancer	0.000202	0.00269	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Doxorubicin—thyroid cancer	0.000199	0.00265	CcSEcCtD
Trisalicylate-choline—Urticaria—Epirubicin—thyroid cancer	0.000197	0.00262	CcSEcCtD
Trisalicylate-choline—Pain—Doxorubicin—thyroid cancer	0.000196	0.00261	CcSEcCtD
Trisalicylate-choline—Constipation—Doxorubicin—thyroid cancer	0.000196	0.00261	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Doxorubicin—thyroid cancer	0.000189	0.00252	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000188	0.00364	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000184	0.00357	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000182	0.00353	CbGpPWpGaD
Trisalicylate-choline—Urticaria—Doxorubicin—thyroid cancer	0.000182	0.00243	CcSEcCtD
Trisalicylate-choline—Pruritus—Epirubicin—thyroid cancer	0.000175	0.00234	CcSEcCtD
Trisalicylate-choline—PTGS2—Disease—TRIM24—thyroid cancer	0.000173	0.00334	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CHST14—thyroid cancer	0.000171	0.00331	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—MINPP1—thyroid cancer	0.00017	0.00329	CbGpPWpGaD
Trisalicylate-choline—Diarrhoea—Epirubicin—thyroid cancer	0.000169	0.00226	CcSEcCtD
Trisalicylate-choline—Dizziness—Epirubicin—thyroid cancer	0.000164	0.00218	CcSEcCtD
Trisalicylate-choline—PTGS2—Disease—CHST14—thyroid cancer	0.000162	0.00314	CbGpPWpGaD
Trisalicylate-choline—Pruritus—Doxorubicin—thyroid cancer	0.000162	0.00216	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000159	0.00307	CbGpPWpGaD
Trisalicylate-choline—Vomiting—Epirubicin—thyroid cancer	0.000157	0.0021	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Doxorubicin—thyroid cancer	0.000157	0.00209	CcSEcCtD
Trisalicylate-choline—Rash—Epirubicin—thyroid cancer	0.000156	0.00208	CcSEcCtD
Trisalicylate-choline—Dermatitis—Epirubicin—thyroid cancer	0.000156	0.00208	CcSEcCtD
Trisalicylate-choline—Headache—Epirubicin—thyroid cancer	0.000155	0.00207	CcSEcCtD
Trisalicylate-choline—PTGS2—Disease—TRIM33—thyroid cancer	0.000154	0.00298	CbGpPWpGaD
Trisalicylate-choline—Dizziness—Doxorubicin—thyroid cancer	0.000152	0.00202	CcSEcCtD
Trisalicylate-choline—Nausea—Epirubicin—thyroid cancer	0.000147	0.00196	CcSEcCtD
Trisalicylate-choline—Vomiting—Doxorubicin—thyroid cancer	0.000146	0.00194	CcSEcCtD
Trisalicylate-choline—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000145	0.0028	CbGpPWpGaD
Trisalicylate-choline—Rash—Doxorubicin—thyroid cancer	0.000144	0.00193	CcSEcCtD
Trisalicylate-choline—Dermatitis—Doxorubicin—thyroid cancer	0.000144	0.00192	CcSEcCtD
Trisalicylate-choline—Headache—Doxorubicin—thyroid cancer	0.000144	0.00191	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000141	0.00272	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—HPGD—thyroid cancer	0.000138	0.00267	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.000137	0.00264	CbGpPWpGaD
Trisalicylate-choline—Nausea—Doxorubicin—thyroid cancer	0.000136	0.00181	CcSEcCtD
Trisalicylate-choline—PTGS2—Metabolism—CHST14—thyroid cancer	0.000136	0.00263	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	0.000116	0.00225	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000112	0.00217	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—HPGD—thyroid cancer	0.00011	0.00212	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TCF7L1—thyroid cancer	0.000103	0.00199	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.56e-05	0.00185	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	9.26e-05	0.00179	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	9.23e-05	0.00178	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.9e-05	0.00172	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—TPR—thyroid cancer	7.94e-05	0.00153	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PRKAR1A—thyroid cancer	7.81e-05	0.00151	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TPR—thyroid cancer	7.52e-05	0.00145	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PRKAR1A—thyroid cancer	7.4e-05	0.00143	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	7.09e-05	0.00137	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.08e-05	0.00137	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—MEN1—thyroid cancer	7.07e-05	0.00137	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—TPR—thyroid cancer	6.3e-05	0.00122	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.3e-05	0.00122	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PRKAR1A—thyroid cancer	6.2e-05	0.0012	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—SLC5A5—thyroid cancer	5.94e-05	0.00115	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CALCA—thyroid cancer	5.63e-05	0.00109	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.62e-05	0.00109	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.57e-05	0.00108	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.32e-05	0.00103	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CDK1—thyroid cancer	5.1e-05	0.000986	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—RXRA—thyroid cancer	4.99e-05	0.000965	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.85e-05	0.000939	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—SLC5A5—thyroid cancer	4.72e-05	0.000912	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NRG1—thyroid cancer	4.09e-05	0.000791	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—RXRA—thyroid cancer	3.96e-05	0.000766	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.85e-05	0.000745	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TERT—thyroid cancer	3.67e-05	0.00071	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HIF1A—thyroid cancer	3.51e-05	0.000679	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PPARG—thyroid cancer	3.15e-05	0.000609	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—BRAF—thyroid cancer	2.91e-05	0.000563	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PPARG—thyroid cancer	2.5e-05	0.000484	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PTGS2—thyroid cancer	2.48e-05	0.000479	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PTEN—thyroid cancer	2.16e-05	0.000418	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PTEN—thyroid cancer	2.05e-05	0.000396	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NRAS—thyroid cancer	1.83e-05	0.000354	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PTEN—thyroid cancer	1.72e-05	0.000332	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—KRAS—thyroid cancer	1.57e-05	0.000304	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HRAS—thyroid cancer	1.34e-05	0.000259	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—AKT1—thyroid cancer	1.25e-05	0.000241	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—AKT1—thyroid cancer	1.18e-05	0.000228	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—AKT1—thyroid cancer	9.89e-06	0.000191	CbGpPWpGaD
